Latest Silence Therapeutics plc Stories
LONDON, March 21, 2012 /PRNewswire/ -- Silence Therapeutics plc [http://silence-therapeutics.com ] (AIM: SLN) ("Silence" or "the Company"), a leading RNA [http://silence-therapeutics.com/content/therapeuticplatform/overview.htm ] interference (RNAi [http://silence-therapeutics.com ]) therapeutics company, today announced the creation of a Scientific Advisory Board (SAB) with the appointment of two Key Opinion Leaders (KOLs) in the area of liver disease, Professor Dr. Dr....
LONDON, March 9, 2012 /PRNewswire/ -- Silence Therapeutics plc [http://silence-therapeutics.com ] (AIM: SLN) ("Silence" or "the Company"), a leading RNA [http://silence-therapeutics.com/content/therapeuticplatform/overview.htm ] interference (RNAi) therapeutics company, responds to comments that the Tuschl I (EP 1309726) patent has been upheld in European Opposition Proceedings without any modification. Concluding on 1 March 2012, the European Patent Office held oral...
LONDON, February 10, 2012 /PRNewswire/ -- -- Tony Sedgwick steps up to Chief Executive Officer from Chief Business Officer -- -- Thomas Christely resigns as a Director of the Company -- Silence Therapeutics plc [http://silence-therapeutics.com ] (AIM: SLN) ("Silence" or "the Company"), a leading RNA [http://silence-therapeutics.com/content/therapeuticplatform/overview.htm ] interference (RNAi)...
LONDON, January 9, 2012 /PRNewswire/ -- - Third collaboration to investigate the potential application of Silence's proprietary RNAi delivery technologies in the development of novel microRNA-based therapeutics Silence Therapeutics plc [http://silence-therapeutics.com ] (AIM: SLN) ("Silence"), a leading RNA [http://silence-therapeutics.com/content/therapeuticplatform/overview.htm ] interference (RNAi) therapeutics company, announces that it has signed an agreement with...
LONDON, January 6, 2012 /PRNewswire/ -- Silence Therapeutics plc [http://www.silence-therapeutics.com ] (AIM: SLN) ("Silence" or the "Company"), a leading RNA [http://silence-therapeutics.com/content/therapeuticplatform/overview.htm ] interference (RNAi) therapeutics company, announces the successful completion of its research work under the Research Collaboration and Delivery Collaboration with its partner AstraZeneca and its biologics arm, MedImmune. The first collaboration...
LONDON, December 20, 2011 /PRNewswire/ -- Silence Therapeutics plc [http://www.silencetherapeutics.com ] (AIM: SLN) ("Silence" or the "Company") a leading global RNA [http://silence-therapeutics.com/content/scienceofrnai/overview.htm ]interference (RNAi) therapeutics company, today announces that application has been sought for 530,000 new ordinary shares of 1 pence each ("Ordinary Shares") to be admitted to trading on AIM. The new Ordinary Shares are being issued in...
LONDON, December 12, 2011 /PRNewswire/ -- Silence Therapeutics plc [http://www.silencetherapeutics.com ] (AIM: SLN) ("Silence" or the "Company"), a leading global RNA interference (RNAi [http://www.silencetherapeutics.com/content/scienceofrnai/overview.htm ]) therapeutics company, announces that the United States Patent and Trademark Office (USPTO) has completed its reexamination of four key RNAi patents that form part of the foundational "Zamore Design Rule" patent families....
LONDON, December 7, 2011 /PRNewswire/ -- Silence Therapeutics plc [http://www.silencetherapeutics.com ] (AIM: SLN) ("Silence" or the "Company"), a leading RNA interference (RNAi [http://www.silencetherapeutics.com/content/scienceofrnai/overview.htm ]) therapeutics company, announces a positive outcome from the oral hearing on 6 December 2011 at the European Patent Office (EPO) over opposition to Silence's granted European Patent EP 1 536 827 "Further use of protein kinase N...
LONDON, November 8, 2011 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company"), a leading RNA interference (RNAi [http://www.silence-therapeutics.com/content/scienceofrnai/overview.htm ]) therapeutics company, today provides an update on recent business and clinical developments. Expansion of business development team Silence today announces the appointment of Dr Georg Buchner as VP Business Development. Georg will work with Tony...
LONDON, September 27, 2011 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence"), a leading RNA interference (RNAi [http://www.silence-therapeutics.com/content/scienceofrnai/overview.htm ]) therapeutics company, today announces that it has entered into an agreement with one of the world's leading global pharmaceutical companies to investigate the application of Silence's proprietary DACC delivery technology for intravenous delivery of short interfering RNA...
